Share-based Payment Arrangement, Expense of BIOGEN INC. from 30 Jun 2010 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BIOGEN INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2010 to 31 Dec 2024.
  • BIOGEN INC. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2024 was $77,500,000, a 37% decline year-over-year.
  • BIOGEN INC. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2024 was $301,500,000, a 9.9% decline year-over-year.
  • BIOGEN INC. annual Share-based Payment Arrangement, Expense for 2024 was $301,500,000, a 9.9% decline from 2023.
  • BIOGEN INC. annual Share-based Payment Arrangement, Expense for 2023 was $274,400,000, a 4.1% decline from 2022.
  • BIOGEN INC. annual Share-based Payment Arrangement, Expense for 2022 was $263,500,000, a 6.9% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BIOGEN INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $301,500,000 $77,500,000 -$20,900,000 -37% 01 Oct 2024 31 Dec 2024 10-K 12 Feb 2025 2024 FY
Q3 2024 $280,600,000 $75,000,000 -$10,200,000 -16% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2024 2024 Q3
Q2 2024 $270,400,000 $72,900,000 +$1,200,000 +1.6% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $271,600,000 $76,100,000 +$2,800,000 +3.5% 01 Jan 2024 31 Mar 2024 10-Q 24 Apr 2024 2024 Q1
Q4 2023 $274,400,000 $56,600,000 +$12,800,000 +18% 01 Oct 2023 31 Dec 2023 10-K 12 Feb 2025 2024 FY
Q3 2023 $287,200,000 $64,800,000 +$900,000 +1.4% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 $288,100,000 $74,100,000 -$16,100,000 -28% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $272,000,000 $78,900,000 -$8,500,000 -12% 01 Jan 2023 31 Mar 2023 10-Q 24 Apr 2024 2024 Q1
Q4 2022 $263,500,000 $69,400,000 -$8,800,000 -15% 01 Oct 2022 31 Dec 2022 10-K 12 Feb 2025 2024 FY
Q3 2022 $254,700,000 $65,700,000 -$8,100,000 -14% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $246,600,000 $58,000,000 -$2,200,000 -3.9% 01 Apr 2022 30 Jun 2022 10-Q 25 Jul 2023 2023 Q2
Q1 2022 $244,400,000 $70,400,000 +$2,200,000 +3% 01 Jan 2022 31 Mar 2022 10-Q 25 Apr 2023 2023 Q1
Q4 2021 $246,600,000 $60,600,000 -$10,200,000 -20% 01 Oct 2021 31 Dec 2021 10-K 14 Feb 2024 2023 FY
Q3 2021 $236,400,000 $57,600,000 -$22,200,000 -63% 01 Jul 2021 30 Sep 2021 10-Q 25 Oct 2022 2022 Q3
Q2 2021 $214,200,000 $55,800,000 -$6,300,000 -13% 01 Apr 2021 30 Jun 2021 10-Q 20 Jul 2022 2022 Q1
Q1 2021 $207,900,000 $72,600,000 -$3,400,000 -4.9% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $204,500,000 $50,400,000 +$87,000,000 +63% 01 Oct 2020 31 Dec 2020 10-K 15 Feb 2023 2022 FY
Q3 2020 $291,500,000 $35,400,000 +$12,400,000 +26% 01 Jul 2020 30 Sep 2020 10-Q 20 Oct 2021 2021 Q3
Q2 2020 $303,900,000 $49,500,000 +$5,500,000 +10% 01 Apr 2020 30 Jun 2020 10-Q 22 Jul 2021 2021 Q2
Q1 2020 $309,400,000 $69,200,000 -$118,200,000 -241% 01 Jan 2020 31 Mar 2020 10-Q 22 Apr 2021 2021 Q1
Q4 2019 $191,200,000 $137,400,000 +$159,800,000 +54% 01 Oct 2019 31 Dec 2019 10-K 03 Feb 2022 2021 FY
Q3 2019 $351,000,000 $47,800,000 -$88,200,000 -218% 01 Jul 2019 30 Sep 2019 10-Q 21 Oct 2020 2020 Q3
Q2 2019 $262,800,000 $55,000,000 -$96,400,000 -233% 01 Apr 2019 30 Jun 2019 10-Q 22 Jul 2020 2020 Q2
Q1 2019 $166,400,000 $49,000,000 +$2,300,000 +4.9% 01 Jan 2019 31 Mar 2019 10-Q 23 Apr 2020 2020 Q1
Q4 2018 $168,700,000 $297,200,000 01 Oct 2018 31 Dec 2018 10-K 03 Feb 2021 2020 FY
Q3 2018 $40,400,000 01 Jul 2018 30 Sep 2018 10-Q 22 Oct 2019 2019 Q3
Q2 2018 $41,400,000 01 Apr 2018 30 Jun 2018 10-Q 24 Jul 2019 2019 Q2
Q1 2018 $46,700,000 01 Jan 2018 31 Mar 2018 10-Q 24 Apr 2019 2019 Q1
Q3 2011 $36,600,000 -$6,200,000 -14% 01 Jul 2011 30 Sep 2011 10-Q 28 Oct 2011 2011 Q3
Q2 2011 $36,100,000 -$13,300,000 -27% 01 Apr 2011 30 Jun 2011 10-Q 26 Jul 2011 2011 Q2
Q3 2010 $42,800,000 01 Jul 2010 30 Sep 2010 10-Q 28 Oct 2011 2011 Q3
Q2 2010 $49,400,000 01 Apr 2010 30 Jun 2010 10-Q 26 Jul 2011 2011 Q2

BIOGEN INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $301,500,000 -$27,100,000 -9.9% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2025 2024 FY
2023 $274,400,000 -$10,900,000 -4.1% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2025 2024 FY
2022 $263,500,000 -$16,900,000 -6.9% 01 Jan 2022 31 Dec 2022 10-K 12 Feb 2025 2024 FY
2021 $246,600,000 -$42,100,000 -21% 01 Jan 2021 31 Dec 2021 10-K 14 Feb 2024 2023 FY
2020 $204,500,000 -$13,300,000 -7% 01 Jan 2020 31 Dec 2020 10-K 15 Feb 2023 2022 FY
2019 $191,200,000 -$22,500,000 -13% 01 Jan 2019 31 Dec 2019 10-K 03 Feb 2022 2021 FY
2018 $168,700,000 -$306,800,000 -222% 01 Jan 2018 31 Dec 2018 10-K 03 Feb 2021 2020 FY
2017 $138,100,000 +$276,200,000 01 Jan 2017 31 Dec 2017 10-K 06 Feb 2019 2018 FY
2016 $138,100,000 -$321,300,000 -175% 01 Jan 2016 31 Dec 2016 10-K 06 Feb 2020 2019 FY
2015 $183,200,000 +$18,200,000 +11% 01 Jan 2015 31 Dec 2015 10-K 01 Feb 2018 2017 FY
2014 $165,000,000 +$18,800,000 +13% 01 Jan 2014 31 Dec 2014 10-K 02 Feb 2017 2016 FY
2013 $146,200,000 +$22,244,000 +18% 01 Jan 2013 31 Dec 2013 10-K 03 Feb 2016 2015 FY
2012 $123,956,000 +$6,609,000 +5.6% 01 Jan 2012 31 Dec 2012 10-K 04 Feb 2015 2014 FY
2011 $117,347,000 -$54,088,000 -32% 01 Jan 2011 31 Dec 2011 10-K 06 Feb 2014 2013 FY
2010 $171,435,000 01 Jan 2010 31 Dec 2010 10-K 05 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.